Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00123305
Other study ID # TG-M-004
Secondary ID
Status Completed
Phase Phase 2
First received July 21, 2005
Last updated November 6, 2014
Start date October 2005
Est. completion date June 2008

Study information

Verified date November 2014
Source ThromboGenics
Contact n/a
Is FDA regulated No
Health authority Belgium: Federal Agency for Medicines and Health Products, FAMHPBelgium: Institutional Review BoardFrance: Ministry of HealthGermany: Federal Institute for Drugs and Medical Devices
Study type Interventional

Clinical Trial Summary

The primary purpose of this study is to evaluate the safety and preliminary efficacy of microplasmin when administered intravenously to patients who have suffered an acute stroke within 12 hours before randomization.


Description:

While the primary objective of the trial is safety evaluation, efficacy assessments will also be obtained, including MRI/MRA (including DWI, PWI and T2 imaging) and plasma surrogate biomarkers. Clinical outcome will also be assessed at 7days, 30 days and 90 days post-treatment. At each of these visits, mortality and neurological assessments (NIHSS, Barthel index, mRankin scale) will be performed. In addition, vital status will be assessed vial a telephone contact at 60 days post-treatment.

The trial will investigate three dose regimens of microplasmin, all of which are within the range of doses previously evaluated in a Phase I trial in healthy volunteers; the planned sample size for the trial is approximately 40 patients.

The study will consist of 3 phases - the Baseline, In-hospital Phase and Follow up Phase. Baseline is from study entry through randomisation; the In-hospital phase is from treatment with study drug through hospital discharge or day 7, whichever occurs first. The follow up phase consists of visits to the hospital 30 days (+ 3 days) from the day of study drug administration. Hospital discharge is defined as the end of the discharge from the acute hospital setting. Discharge may be to home, to a rehabilitation setting or to a non-acute hospital setting.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date June 2008
Est. primary completion date May 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria:

- Acute ischemic stroke with onset within 12 hours before randomization with baseline NIHSS > 6 and < 22

Exclusion Criteria:

General Exclusion Criteria

- Participation in another study with an investigational drug or device within the previous 30 days, prior participation in the present study, or planned participation in another trial within the time frame of the current trial

- Symptoms suggestive of subarachnoid hemorrhage, even if CT scan or MRI is negative for hemorrhage

- Women known to be pregnant, lactating, or having a positive or indeterminate pregnancy test

Stroke Related Exclusion Criteria

- Neurological deficit that has led to stupor or coma (National Institutes of Health Stroke Scale [NIHSS] Level Of Consciousness Item 1a score >or=2)

- High clinical suspicion of septic embolus

- Thrombosis involving cerebral veins

- Rapidly improving neurological signs at any time before initiation of study drug administration

Imaging Related Exclusion Criteria

- Hemorrhagic transformation or intracerebral hemorrhage observed on baseline CT of the brain or gradient recalled echo (GRE) magnetic resonance imaging

- CT or MRI evidence of nonvascular cause for the neurological symptoms

- Large hypodensity on CT involving > 1/3 of the middle cerebral artery (MCA) territory

- Baseline DWI volume > 1/3 of the MCA territory

- Signs of mass effect causing shift of midline structures on CT or MRI

- Unable to undergo MRI (i.e., ferrous implants, cardiac pacemakers, agitation, claustrophobia or known sensitivity to MRI contrast agents)

Safety Related Exclusion Criteria

- Congenital or acquired coagulopathy causing either of the following

1. activated partial thromboplastin time prolongation greater than 2 seconds above the upper limit of normal (ULN) for local laboratory

2. International normalized ratio (INR) of 1.4 or more.

- Uncontrolled hypertension defined as a systolic blood pressure > 180 mm Hg or a diastolic blood pressure > 100 mm Hg on 3 separate occasions at least 10 minutes apart or requiring continuous intravenous (IV) therapy.

- History of stroke within the previous 3 months

- Seizures at any time between stroke onset to planned initiation of study drug

- History of intracranial hemorrhage

- History of surgery, lumbar puncture, biopsy or trauma to internal organs within the previous 30 days.

- Major trauma at the time of stroke

- Head trauma within the previous 90 days.

- Known bleeding diathesis.

- Baseline platelet count < 100 X 10^9/L.

- Blood glucose > 400mg/dl or <50 mg/dl if administration of glucose does not rapidly reverse neurological deficit

Exclusion Criteria That May Potentially Interfere with Outcome Assessment

- Life expectancy <3 months

- Other serious illness that in the opinion of the investigator may confound clinical assessment (e.g. hepatic, cardiac, or renal failure, advanced cancer)

Exclusion Criteria Related to Concomitant Medication

- If treatment with tPA is indicated

- Treatment with rtPA or any other thrombolytic agent for the qualifying stroke

- Administration of intra-arterial or systemic thrombolytic therapy in previous 7 days

- Need for antiplatelet agent, unfractionated or heparin-related products, direct thrombin inhibitor, oral anticoagulant within 24 hours after treatment bolus.

- Treatment with low molecular weight heparin, direct thrombin inhibitor, or GPIIb/IIIa antagonists within 48 hours prior to randomisation

- Treatment with vitamin-K antagonists or heparin (or heparin-related compounds) which results in either an INR>1.4 or an aPTT>2 times control (ULN for the hospital laboratory)

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Microplasmin
1mg/kg bolus of microplasmin solution followed by 1,2 or 3mg/kg infusion of mircroplasmin solution.
Microplasmin
1mg/kg bolus of placebo solution followed by 1,2 or 3mg/kg infusion of placebo solution

Locations

Country Name City State
Austria Universitatsklinik fur Neurologie Graz
Austria AKH Linz Neurolog Abt Linz
Austria Allgemeines Offentliches Krankenhaus der Linz
Austria Landesnervenklinik Wagner-Jauregg Linz
Belgium Cliniques Universitaires St Luc Brussels
Belgium Gasthuisburg Hospital Leuven
Germany Universitätsklinikum Erlangen Erlangen
Germany Universitatsklinikum Essen Essen
Germany Klinikum der J.W Goethe Univeristy Frankfurt
Germany Universitatsklinikum Freiburg Freiburg
Germany Georg August Universitat Gottingen Gottingen
Germany Universitatskrankenhaus Hamburg-Eppendorf Hamburg
Germany Universitatsklinikum Leipzig Leipzig
Germany Klinikum Minden, Chefarzt der Neurologischen Klinik Minden
Germany Klinikum rechts der Isar der TU München München
Germany HSK Dr. Horst Schmidt Hospital Wiesbaden

Sponsors (1)

Lead Sponsor Collaborator
ThromboGenics

Countries where clinical trial is conducted

Austria,  Belgium,  Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Intracranial haemorrhage 24 hours and Day-7 Yes
Primary Change from Baseline in NIHSS Day7 and Day-90 No
Secondary Barthel Index and modified Rankin scale Day-90 No
Secondary Markers of systemic lysis Baseline, end of treatment, 6, 12, 24, 72 and 96 hours Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05378035 - DOAC in Chinese Patients With Atrial Fibrillation
Completed NCT03574038 - Transcranial Direct Current Stimulation as a Neuroprotection in Acute Stroke N/A
Completed NCT03679637 - Tablet-based Aphasia Therapy in the Acute Phase After Stroke N/A
Completed NCT03633422 - Evaluation of Stroke Patient Screening
Completed NCT04088578 - VNS-supplemented Motor Retraining After Stroke N/A
Withdrawn NCT04991038 - Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients N/A
Not yet recruiting NCT05534360 - Tenecteplase Treatment in Ischemic Stroke Registry
Withdrawn NCT05786170 - ERILs Und SNILs Unter SOC N/A
Not yet recruiting NCT04105322 - Effects of Kinesio Taping on Balance and Functional Performance in Stroke Patients N/A
Recruiting NCT03132558 - Contrast Induced Acute Kidney in Patients With Acute Stroke N/A
Completed NCT02893631 - Assessment of Hemostasis Disorders in rtPA-treated Patients Requiring Endovascular Treatment for Ischemic Stroke
Active, not recruiting NCT02274727 - Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL-Study
Completed NCT02225730 - Imaging Collaterals in Acute Stroke (iCAS)
Terminated NCT01705353 - The Role of HMGB-1 in Chronic Stroke N/A
Active, not recruiting NCT01581502 - SAMURAI-NVAF Study: Anticoagulant Therapy for Japanese Stroke Patients With Nonvalvular Atrial Fibrillation (NVAF) N/A
Completed NCT01182818 - Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry Disease N/A
Completed NCT00761982 - Autologous Bone Marrow Stem Cells in Middle Cerebral Artery Acute Stroke Treatment. Phase 1/Phase 2
Completed NCT00535197 - Autologous Bone Marrow Stem Cells in Ischemic Stroke. Phase 1/Phase 2
Terminated NCT00132509 - FRALYSE Trial: Comparison of the Classical Rt-PA Procedure With a Longer Procedure in Acute Ischemic Stroke Phase 2
Recruiting NCT05760326 - Diagnostic and Prognostic Role of Clot Analysis in Stroke Patients